Sep 23 2026 10:01 PM EST
Altria Shares Slip After Q2 EPS Miss and Guidance Narrowed
Altria Group (NYSE: MO) posted Q2 2026 net revenues of $6.111 billion, essentially unchanged from a year earlier, while adjusted diluted earnings per share came in at $1.48, missing the consensus estimate of $1.49. The earnings miss coincided with an approximately 8% decline in the share price on the day of the release.
Revenue net of excise taxes rose 1.2% to $5.356 billion. Reported diluted EPS fell 2.8% to $1.37. Management narrowed full‑year 2026 adjusted EPS guidance to a range of $5.61–$5.72, implying 3.5%‑5.5% growth over the 2025 base of $5.42.
Q2 Earnings Miss and Stock Reaction
The adjusted EPS miss of $0.02 versus consensus was the primary catalyst for the ‑8% move in the stock. Analysts noted that the miss reflected a modest slowdown in the smoke‑able segment, which was partially offset by growth in oral‑tobacco products.
Guidance, Dividend and Share‑Buyback
Altria reaffirmed its dividend at $1.11 per share, translating to an annualized payout of $4.44 and a yield of roughly 6.4%. The board also expanded the share‑repurchase program to $2 billion, extending the authorization to 31 December 2026.
Smoke‑Free Portfolio Momentum
The on! nicotine‑pouch line continued to expand, with FDA authorizing four new On Plus products on 4 April 2026. Oral‑tobacco share of the overall tobacco mix rose to 59.9% in Q2 2026, up 8.1 percentage points year‑over‑year. Altria’s “Optimize & Accelerate” cost‑savings program remains in place, targeting roughly $600 million of cumulative savings.
Macro and Regulatory Context
The company cited persistent inflation and higher gasoline prices as headwinds that could curb adult nicotine‑consumer spending. State excise‑tax hikes in Maine and Washington, effective 1 January 2026, added $3.14 billion in tax costs in 2025 and are expected to pressure volumes further. Conversely, the withdrawal of the proposed federal menthol‑cigarette ban on 21 January 2026 removed a potential multi‑billion‑dollar revenue threat.
Valuation and Analyst Sentiment
Altria trades at a forward P/E of roughly 10.5–10.97×, slightly below its historic median. Consensus analyst coverage rates the stock as “Hold” with an average price target of $70–$71, implying modest upside from the current price of around $68.6.
Risks and Uncertainties
Key risks include continued decline in cigarette volumes, ongoing FDA scrutiny of e‑vapor and heated‑tobacco products, the permanent ban on NJOY ACE devices, and the impact of state excise‑tax increases on price‑sensitive consumers. Additionally, competition from rival smoke‑free portfolios and potential macro‑economic slowdown could limit the pace of oral‑nicotine growth.